Skip to main content
Clinical Trials/NCT03970291
NCT03970291
Completed
Not Applicable

Impact of Nociceptive-Level (NOL) Intraoperative Guided Fentanyl Analgesia Versus Standard Clinical Care (SCC) for Elective Major Abdominal Surgery

Medasense Biometrics Ltd1 site in 1 country95 target enrollmentNovember 1, 2019
ConditionsAnesthesia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia
Sponsor
Medasense Biometrics Ltd
Enrollment
95
Locations
1
Primary Endpoint
Pain score
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Recently, a newly developed index, the Nociceptive Level (NOL) index, was validated and showed superiority over heart rate and blood pressure for recognition and grading of intense and mild nociceptive stimuli during surgery under general anesthesia.

We hypothesize that compared with standard management, NOL-guided anesthesia will lead to reduced postoperative pain scores, and during anesthesia, to increased hemodynamic stability.

Detailed Description

Uncontrolled postoperative pain may result in significant clinical, psychological, and socioeconomics consequences. Not only does inadequate pain management following surgery result in increased morbidity and mortality but it also may delay recovery, result in unanticipated readmissions, decrease patient satisfaction, and lead to chronic persistent postsurgical pain. Pain is multifactorial in nature and understanding both the complexity of pain and its side effects is imperative to achieve a successful surgical outcome. Nociception/analgesia are currently assessed by monitoring changes in heart rate (HR), blood pressure (BP), and other indirect parameters which are not sensitive or specific to nociception. As a result, the patient may be given insufficient analgesia which can promote postoperative pain, or excessive analgesia which can result in overdosing and related complications.

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
June 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years old.
  • Elective major laparoscopic abdominal surgical, urologic or gynecologic procedures under general anesthesia.
  • Patient able to provide informed consent

Exclusion Criteria

  • Use of any type of anesthesia other than general anesthesia (neuraxial, epidural analgesia or local regional anesthesia, e.g. transversus abdominal plane block)
  • Patients with rhythm other than sinus cardiac rhythm, implanted pacemakers, α2-adrenergic agonists and β1-adrenergic antagonists
  • Pregnancy/lactation
  • Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic seizures)
  • Abuse of alcohol or illicit drugs within the last 6 months
  • Chronic pain conditions - pain in 1 or more anatomic regions that persists or recurs for longer than 3 months and is associated with significant emotional distress or significant functional disability.
  • Opioid tolerant - if for at least 1 week the patient has been receiving oral morphine 60 mg/day; transdermal fentanyl 25 mcg/hour; oral hydromorphone 8 mg/day; oral oxymorphone 25 mg/day; or an equianalgesic dose of any other opioid
  • Chronic use of psychoactive drugs within 90 days prior to surgery
  • Allergy or intolerance to any of the study drugs
  • History of severe cardiac arrhythmias within the last 12 months

Outcomes

Primary Outcomes

Pain score

Time Frame: Through study completion, about 8 months

Change in pain score in the PACU using the visual analog scale (VAS)

Secondary Outcomes

  • Total intraoperative fentanyl(Through study completion, about 8 months)
  • Inadequate analgesia/anesthesia events(Through study completion, about 8 months)

Study Sites (1)

Loading locations...

Similar Trials